Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

Core Viewpoint - Kymera Therapeutics, Inc. has announced a public offering of $602.0 million in common stock to advance its pipeline of degrader programs and for general corporate purposes [1][2]. Group 1: Offering Details - Kymera is selling 7,000,000 shares at a public offering price of $86.00 per share, with an additional option for underwriters to purchase up to 1,050,000 shares [1]. - The gross proceeds from the offering are expected to be approximately $602.0 million before deducting underwriting discounts and commissions [1]. - The offering is anticipated to close on December 11, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance Kymera's pipeline of preclinical and clinical degrader programs targeting large patient populations and for working capital [2]. Group 3: Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative medicines for immunological diseases [6]. - The company aims to provide a new generation of oral small molecule therapies that are highly effective and convenient for patients [6].